(Q38576508)

PubMed publication ID

26320066

4 September 2017

title

Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6295669&resulttype=core&format=json

13 May 2020

5

Steven A Rosenberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6295669&resulttype=core&format=json

13 May 2020

author name string

Steven A Feldman

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6295669&resulttype=core&format=json

13 May 2020

Yasmine Assadipour

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6295669&resulttype=core&format=json

13 May 2020

Isaac Kriley

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6295669&resulttype=core&format=json

13 May 2020

Stephanie L Goff

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6295669&resulttype=core&format=json

13 May 2020

language of work or name

1 reference

12 June 2015

1 reference

PubMed publication ID

4 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6295669&resulttype=core&format=json

13 May 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6295669&resulttype=core&format=json

13 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6295669&resulttype=core&format=json

13 May 2020

page(s)

626-639

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6295669&resulttype=core&format=json

Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer.

13 May 2020

cites work

1 reference

12 December 2020

Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7

1 reference

12 December 2020

Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).

1 reference

12 December 2020

Lymphocyte infiltrates as a prognostic variable in female breast cancer

1 reference

12 December 2020

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

1 reference

12 December 2020

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

1 reference

12 December 2020

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte

1 reference

12 December 2020

Cancer/testis antigens, gametogenesis and cancer

1 reference

12 December 2020

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

1 reference

12 December 2020

Telomere length of transferred lymphocytes correlates with in vivo persistence and tumor regression in melanoma patients receiving cell transfer therapy.

1 reference

12 December 2020

Adoptive transfer of allogeneic cytotoxic T lymphocytes equipped with a HLA-A2 restricted MART-1 T-cell receptor: a phase I trial in metastatic melanoma

1 reference

12 December 2020

Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience

1 reference

12 December 2020

T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells

1 reference

12 December 2020

Cancer regression in patients after transfer of genetically engineered lymphocytes

1 reference

12 December 2020

Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes

1 reference

12 December 2020

Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma

1 reference

12 December 2020

Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma

1 reference

12 December 2020

Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions

1 reference

12 December 2020

Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.

1 reference

12 December 2020

Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma

1 reference

12 December 2020

Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells

1 reference

12 December 2020

Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy

1 reference

12 December 2020

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

1 reference

12 December 2020

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma

1 reference

12 December 2020

Genome-wide analysis of cancer/testis gene expression

1 reference

12 December 2020

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

12 December 2020

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

1 reference

12 December 2020

A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity

1 reference

12 December 2020

Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells

1 reference

12 December 2020

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

1 reference

12 December 2020

Minimal amino acid exchange in human TCR constant regions fosters improved function of TCR gene-modified T cells

1 reference

12 December 2020

Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l

1 reference

12 December 2020

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

1 reference

12 December 2020

The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

1 reference

12 December 2020

Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL.

1 reference

12 December 2020

Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice

1 reference

12 December 2020

A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.

1 reference

12 December 2020

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

1 reference

12 December 2020

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

12 December 2020

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

1 reference

12 December 2020

Establishment and large-scale expansion of minimally cultured "young" tumor infiltrating lymphocytes for adoptive transfer therapy

1 reference

12 December 2020

In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor

1 reference

12 December 2020

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy

1 reference

12 December 2020

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

1 reference

12 December 2020

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

1 reference

12 December 2020

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

1 reference

12 December 2020

Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma

1 reference

12 December 2020

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

1 reference

12 December 2020

Ten-year relative survival and causes of death in elderly patients treated with R-CHOP or CHOP in the GELA LNH-985 trial

1 reference

12 December 2020

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

1 reference

12 December 2020

Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma

1 reference

12 December 2020

Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

1 reference

12 December 2020

Efficacy of adoptive cell transfer of tumor-infiltrating lymphocytes after lymphopenia induction for metastatic melanoma

1 reference

12 December 2020

Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients

1 reference

12 December 2020

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia

1 reference

12 December 2020

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma

1 reference

12 December 2020

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

1 reference

12 December 2020

Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity

1 reference

12 December 2020

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

1 reference

12 December 2020

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

1 reference

12 December 2020

Collapse of the tumor stroma is triggered by IL-12 induction of Fas.

1 reference

12 December 2020

Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.

1 reference

12 December 2020

Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies

1 reference

12 December 2020

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

1 reference

12 December 2020

Phenotype and function of T cells infiltrating visceral metastases from gastrointestinal cancers and melanoma: implications for adoptive cell transfer therapy

1 reference

12 December 2020

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells

1 reference

12 December 2020

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

1 reference

12 December 2020

Tumor-infiltrating lymphocytes expressing the tissue resident memory marker CD103 are associated with increased survival in high-grade serous ovarian cancer.

1 reference

12 December 2020

Phase I trial of a recombinant yeast-CEA vaccine (GI-6207) in adults with metastatic CEA-expressing carcinoma.

1 reference

12 December 2020

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

1 reference

12 December 2020

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

1 reference

12 December 2020

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors

1 reference

12 December 2020

Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer

1 reference

12 December 2020

A phase I study of PRO131921, a novel anti-CD20 monoclonal antibody in patients with relapsed/refractory CD20+ indolent NHL: correlation between clinical responses and AUC pharmacokinetics

1 reference

12 December 2020

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

1 reference

12 December 2020

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

1 reference

12 December 2020

Chimeric antigen receptor T cells for sustained remissions in leukemia

1 reference

12 December 2020

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

1 reference

12 December 2020

Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins

1 reference

12 December 2020

Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report

1 reference

12 December 2020

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

12 December 2020

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

1 reference

12 December 2020

Biological Activity of Recombinant Human Interleukin-2 Produced inEscherichia coli

1 reference

12 December 2020

B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes

1 reference

12 December 2020

Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies.

1 reference

12 December 2020

Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes

1 reference

12 December 2020

Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection

1 reference

12 December 2020

Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes

1 reference

12 December 2020

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

1 reference

12 December 2020

Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy

1 reference

12 December 2020

Isolation and characterization of tumor-infiltrating lymphocytes from cervical carcinoma

1 reference

12 December 2020

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer

1 reference

12 December 2020

CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy

1 reference

12 December 2020

Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers

1 reference

12 December 2020

Growth of tumor-infiltrating lymphocytes from human solid cancers: summary of a 5-year experience

1 reference

12 December 2020

Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens

1 reference

12 December 2020

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

1 reference

12 December 2020

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

1 reference

12 December 2020

10.1053/J.SEMINONCOL.2015.05.005

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6295669&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6295669&resulttype=core&format=json

13 May 2020

PubMed publication ID

26320066

1 reference